posted on 2015-03-09, 00:00authored byShinae Park, Yong-Uk Kwon
A series of linear and cyclic peptoids,
which were expected to
possess better pharmacokinetic properties and biological activities
for blocking the interaction between apolipoprotein E and amyloid-β,
were designed and synthesized as possible therapeutic agents. Peptoids
were easily synthesized on solid-phase by the submonomer strategy
and polar side chain-containing amines were effectively introduced
under the modified reaction conditions. For the synthesis of cyclic
peptoids, β-alanine protected with the 2-phenylisopropyl group,
which could be selectively removed by 2% TFA, was used as a primary
amine to afford a complete peptoid unit. The macrolactamization between
the carboxylic acid of β-alanine moiety and terminal amine of
peptoids was successfully performed in the presence of the PyAOP coupling
agent on solid-phase in all the cases, providing various sizes of
cyclic peptoids. In particular, some cyclic peptoids prepared in this
study are the largest in size among cyclic peptoids reported to date.
The synthetic strategy which was adopted in this study can also provide
a robust platform for solid-phase construction of cyclic peptoid libraries.
Currently, synthetic peptoids have been used to test interesting biological
activities including the ApoE/Aβ interaction inhibition, nontoxicity,
the blood-brain barrier permeability, etc.